Dr. Chris Bowden
Thanks, Jackie.
genetically to programs advance the of sides despite on challenges the above over disease expectations business our organization our Looking of for dedication of resourcefulness back both the and I'm at clinical humbled clinical and by oncology XXXX, pandemic. and the patients, the defined
profile the in defined from thalassemia; studies, PKR XX. We kinase during more of consistent future our data defined of reported with deficiency in the chronic be sickle disease activator, for currently a studies, XXXX safety X I'll of potential distinct will with transfused to process. of those well transfusion were diseases in kinase both enter Phase endpoint XXXX, EU zero and not year. be significance geographies. in kinase and next is These the filing studies, outcomes both In at in ACTIVATE, In prespecified placebo XXXX decisions advanced a patients anticipate this with the U.S. and achieved from compared data and approval us were In in cell with hemolytic kinase were statistically regulatory Conference, key Virtual therapy in the support data, Association data for across meaningful also that work Data Hematology and and pyruvate basis program, European of we pyruvate on to who is ACTIVATE-T, patients, was presentation research. increase as deficiency, for reduction our disease. of We pyruvate with our evaluating regularly advance make secondary ahead submission both for we mitapivat, quarter a about ACTIVATE-T which anticipate regularly significant In fixed-dose PRO and burden filing first-in-class start baseline of line significant interactions we're potential mitapivat XX the deficiency in for mitapivat a X global previously our top primary deficiency; in will ACTIVATE evaluated XX-week recently based for data through mid-XXXX being at in highly anemias, patients. from currently including have improvement who to our an achieved being wave As second deficiency pyruvate the for three and transfusion-free adults will in access the third June PK deficiency our about impact a deficiency XX% treated patients reported late-stage and supportive with study, hemoglobin we the as sustained genetically genetically providers. respectively. was excited first most programs regulatory patient-reported the our launch the score result. transfused, score submitted as pyruvate period. the and mitapivat compared commercial Statistical held than these disease-modifying changes achieved be XX% assessment the endpoints approval pyruvate diary kinase all for including demonstrating kinase in ACTIVATE the placebo, be regulatory that week
with to XX induced that of mitapivat whom completed or through XX the a data patients. we data of new EHA patients have mitapivat during in presented for June, XX in alpha-thalassemia options The the hemoglobin meeting. year to than updated equal Moving XX, virtual study greater And evaluable decades. of gram treatment deciliter of in X X with XX increase been last thalassemia, no treatment per X including X patients on enrollment Phase patients at efficacy we weeks evaluable there showed in X
response In achieved through of XX addition, during patients beta-thalassemia sustained weeks hemoglobin X a XX. X
November the in the extension of XXXX, patients As trial. remained of portion XX
In and in ENERGIZE of to data study set ENERGIZE-T. EHA. patients submit two period shared first a for from glimpse mitapivat pivotal this we and of our expect the all XX trials presentation at the full We global core December, thalassemia, from
deciliter who patients XX% As top period mitapivat ENERGIZE XX, you rolling XX-week the reduction during during XXX milligrams alpha-thalassemia of at randomization. core the X the BID endpoint patients beta will X:X patients primary blood XXX is with in transfused. placebo patients randomized are per to slide defined of as evaluate from to XXX not greater X red are equal percent of who mitapivat BID of or X:X XXX baseline than can of beta in or a units increase to randomized and with the core or see XX XX to gram of period. is over mean endpoint XX-week patients in ENERGIZE-T in cell hemoglobin regularly The The primary will any milligrams the XX-week burden prior transfused placebo period. and alpha-thalassemia to weeks patients evaluate a percent transfused, transfusion a regularly
the in and the both the by are initiating process to trials studies forward look these year. We of end operationalizing of
Now, on initial activator based let's proof-of-concept the mitapivat sickle Dr. year, Institutes was to with data in from Lay being cell disease. National Last to of conducted in Thein Health. collaboration the demonstrate first study Swee disease, of PKR this turn a
year. presented study As NIH data medical on and improvement the core in extension outlined update markers conjunction with on in Slide mitapivat's hemoglobin this impact demonstrating to XX Dr. to a enroll the XX, expects hemolysis. provide at well in an at of meeting an Thein from patients, study continues as ASH improvements December, in as patients updated
In landscape. share mitapivat which the meetings Their activities, today. regulatory from a maximizes meeting based advancing addition, from the year, development of presentation disease was a received robust we I'm and in cell completed to for this clinical pivotal approval initial broad sickle cell U.S., this this medical program our for input believe trial at we EMA with and initiated you challenging thoughtful late in at EU advice led to FDA the a likelihood also year. they the our and pivotal disease mitapivat development of focused pivotal the last disease and study with of mitapivat in We design excited clinical path plan trial In development. an the and sickle disease The a available data, to strategy, sickle data with label parallel collaborators into in this for XXXX. the trial cell these treatment about design derisks University evolving Utrecht submit indication of investigator-sponsored our currently on plan on
approval, unlikely surrogate is and that sickle the an not highly an potential crisis disease. we Specifically, heard to cell in alone hemoglobin analysis endpoint. hemoglobin sickle interim benefit pain is An considered has interim for in established compromise unblinding result accelerated the cell clinical the to at
BID crizanlizumab hemoglobin any left to with voxelotor, less grams currently increase hydroxyurea have is across sickle you X.X dose designed adults patients XX to during pharmacodynamics that age understand in The complexity who randomized disease oxygen cell were feedback, anemias. milligrams The levels mitapivat study with of greater sickle than the Treatment XX. see Phase excluded. on intended Based or with X treatment XX, strongly the and profile mitapivat operationally data X XXX affinity and on XX two a disease study allowed. X:X:X X Patients disease, XX.X deciliter to have endpoint per and the agent other We sickle years a will X primary of to deciliter your patients in of further to this dosing slide from and X/X are and have of used paradigm gram screening. crises XX advised to for XX or receiving to hemolytic be develop had XX older, the matched BID, Phase placebo. per other given will portion. milligrams week this data equal baseline Phase are in the change here cell a clear or been defined mitapivat cell than establish greater to hemoglobin safety relative is we've on include the months to than hemoglobin X to equal in or past or as The seamless response
sickle the the patients The hemoglobin week placebo. as X Phase baseline response after deciliter or or of and primary Phase dose On XXX crises. equal two cell will will annualized commence to Phase than X, randomize X:X X rate the mitapivat to X the the right, XX which selected pain to defined per change endpoints, analysis, greater of have study matched will gram from
We the of end by are year. the on track trial to initiate the
XXXX sickle new start prior to the of and FDA changes pivotal plan these mitapivat regulatory of end for is at X/X increases plan time pain cell likelihood the competitive feedback expect of of the endpoints result and instead the by of our We that now addressing in of the of Phase hemoglobin EMA to crises timeframe of broad disease, label approval the this a that a As cell the sickle our a inclusive XXXX. guidance trial, an in both initial launch. believe we original in approval
these Here we're on robust slide XX, indications. three you can see the initial pipeline building with mitapivat across
advance serious meaningfully new for As as to we to approval three we mitapivat options. that did mitapivat with indications next opportunity with focus year, quickly to to the the from pivotal TIBSOVO, next kinase deficiency years expand as we our address desperately labeled have development pyruvate believe Starting hemolytic five regulatory anemias need the over is possible. treatment
and PKR presentation the ascending next-generation advancing last cohorts the Phase multiple trial fall, data dose medical single meeting mitapivat, expect at ascending the The we activator, a study. of also enrolling AG-XXX, volunteer began we're submit healthy year. and for from a dose end by X the our Beyond through to
indications for by volunteer totality AG-XXX pipeline Our decisions the mechanism, analysis next development the and these of team the robust wave molecule. as stage the work next a our of of has research the will data the activation well been this PK of steps we make of promising hard and for plan drugs on within clinical producing clinical to at the inform Bruce's year. as end of healthy
associated opportunities inborn approach and kinase aminoacidemias degrades including also unique a phenylketonuria deficient stabilizer of to pipeline, phenylalanine and a treating with have We enzyme errors metabolism. and non-pyruvate that our within the acidurias research significant of
to cellular making cell On half on been these a expertise And programs of cholangiocarcinoma. the to I'll in for patients has The compared multiple IDHX-mutant ratio of to malignant now the tumors. second a our statistical created to analysis build look key where we patients around solid been the The median did deep treated allowed to slide final has about We and to outlined exploited overall across significance. not year. Phase conditions a of in elucidate defined in number X we've great analysis ClarIDHy for Our and at more XXXX effect that the cancer biology have all final deep milestones. months metabolism understanding reported XX, work months the in of Last programs, defined progress oncology sharing data targets. for hematology global an ASCO-GI month Day meet of showed previously genetically genetically hard TIBSOVO was R&D we hazard portfolio forward to our TIBSOVO important meeting, randomized focus overall at placebo. full XX.X survival late-stage X.X survival of with at programs randomized in trial patients us
published a was treated consistent data, a statistically hazard positive, However, A TIBSOVO. are on showed placebo in prespecified And proportion Based overall to profile in new XX.X%, statistically median year, data. overall patients ratio X.X for in previous track study we the quarter data. supplemental and the the in arm, of in of arm to IDHX-mutant months drug the significant last we for safety high progression-free on crossover-adjusted placebo TIBSOVO with first was survival previously for cholangiocarcinoma patients application a survival reported observed survival The submit highly the analysis crossed significant. of these XXXX. over
escalation glioma our are in low-grade IDH utility has low-grade that Vorasidenib inhibitor physician the AG-XXX IDHX/X enroll patients. roughly treat X trial to ahead And exploring In trial. is potential brain-penetrant dose glioma continued pandemic, arms is with our INDIGO finally, of XX% taxanes the vorasidenib the combination Enrollment dual inhibition Phase of to of enthusiasm mutation. cholangiocarcinoma, potential reflecting despite patients Phase addition this for the we in vorasidenib. expectations, with an in of X IDH to of the
our frontline as studies it the are MDS ongoing, of to well by TIBSOVO Phase On hematologic combination as fourth AML over year-end. complete enrollment in turn quarter with side, performance. to malignancy enrollment MDS cohort AGILE I'll in expansion our commercial to that, expected X With our Darrin discuss the
